A glucagon/GLP-1 dual agonist cuts weight in diabetes with obesity

Design

Phase 3, multinational, randomised, double-blind, placebo-controlled, 1:1:1

Population

752 adults with type 2 diabetes and BMI 27 or more; mean BMI 36.5, HbA1c 7.4%

Primary outcome

Percent weight change and proportion losing at least 5% at week 76

Effect

-8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% placebo; 5% loss 57.6%/64.5%/35.1%

SYNCHRONIZE-2, a multinational double-blind phase 3 trial, randomised 752 adults with type 2 diabetes and a BMI of 27 or more to once-weekly subcutaneous survodutide (3.6 mg or 6.0 mg) or placebo, with weight change and the proportion losing at least 5% at week 76 as co-primary endpoints. Survodutide is an investigational dual agonist at the glucagon and GLP-1 receptors.

Weight fell 8.2% at 3.6 mg and 9.8% at 6.0 mg against 3.9% with placebo, and at least 5% loss occurred in 57.6%, 64.5% and 35.1% respectively. HbA1c, from a baseline of 7.4%, improved by about 0.8 to 0.9 percentage points on active drug versus 0.2 on placebo. Gastrointestinal effects were the commonest adverse events and were generally mild to moderate.

The result adds a dual-mechanism agent to the incretin field, with weight loss in the range of established GLP-1 therapy and a modest glycaemic effect. It is investigational and not yet approved anywhere; the trial measured weight and glycaemia, not cardiovascular or renal outcomes.

• Survodutide is a dual glucagon and GLP-1 receptor agonist, given once weekly.
• Weight fell about 9.8% at the 6.0 mg dose versus 3.9% with placebo at 76 weeks.
• At least 5% weight loss occurred in roughly two-thirds on active drug, a third on placebo.
• HbA1c improved by about 0.8-0.9 points from a 7.4% baseline.
• The drug is investigational and not yet approved; gastrointestinal effects are common.

Why it matters

It signals a dual-mechanism option joining the incretin class rather than a replacement for proven therapy today.

Don't overread it

This is a phase 3 weight and glycaemia trial of an unapproved drug, not a cardiovascular or renal outcomes study.

The statistics, in plain English

The 6-percentage-point weight gap over placebo is clinically meaningful, and the confidence intervals exclude no effect; the HbA1c change is modest, so this is primarily a weight result with a secondary glycaemic one.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.